Long-term rituximab safe for patients with wegener's

July 2, 2012
Long-term rituximab safe for patients with wegener's
Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener's), a primary systemic small vessel vasculitis, according to a study published online June 21 in Arthritis & Rheumatism.

(HealthDay) -- Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener's), a primary systemic small vessel vasculitis, according to a study published online June 21 in Arthritis & Rheumatism.

Rodrigo Cartin-Ceba, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues examined the efficacy and safety of B-cell depletion in 53 with refractory who had received at least two courses of rituximab for relapses or to remain in remission. All patients except one had antineutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3).

Patients received a median of four courses of rituximab treatment. The researchers found that B cells were depleted in all cases, returning after a median of 8.5 months. All relapses occurred after B cells were reconstituted, and all except one were accompanied or preceded by an increase in ANCA levels. There were infusion-related adverse events in 16 patients, and 30 infections required treatment when B cells were depleted.

"Rituximab [appears] effective and safe for induction and maintenance of remission in patients with relapsing GPA," Cartin-Ceba and colleagues conclude. "Preemptive retreatment decisions can be individualized based on serial B lymphocyte and PR3-ANCA monitoring."

Several authors disclosed being investigators on clinical trials supported by pharmaceutical companies, including Genentech, which manufactures .

Explore further: B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome

October 20, 2011
Chronic fatigue syndrome (CFS) may be alleviated by the anti-cancer drug Rituximab, suggesting that the source of the disease could lie in the immune system, according to a new study published Oct. 19 in the online journal ...

Brentuximab vedotin effective in large-cell lymphoma

May 24, 2012
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, ...

Recommended for you

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).

Osteoarthritis could be prevented with good diet and exercise

May 12, 2017
Osteoarthritis can potentially be prevented with a good diet and regular exercise, a new expert review published in the Nature Reviews Rheumatology reports.

Rodents with trouble walking reveal potential treatment approach for most common joint disease

May 11, 2017
Maintaining the supply of a molecule that helps to nourish cartilage prevented osteoarthritis in animal models of the disease, according to a report published in Nature Communications online May 11.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.